NO317296B1 - Hypnotisk <beta>- karbolinderivater, fremgangsmater til deres fremstilling og deres anvendelse som legemiddelprodukt - Google Patents
Hypnotisk <beta>- karbolinderivater, fremgangsmater til deres fremstilling og deres anvendelse som legemiddelprodukt Download PDFInfo
- Publication number
- NO317296B1 NO317296B1 NO20004638A NO20004638A NO317296B1 NO 317296 B1 NO317296 B1 NO 317296B1 NO 20004638 A NO20004638 A NO 20004638A NO 20004638 A NO20004638 A NO 20004638A NO 317296 B1 NO317296 B1 NO 317296B1
- Authority
- NO
- Norway
- Prior art keywords
- methoxy
- quinolizin
- general formula
- derivatives
- ethyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 36
- 230000000147 hypnotic effect Effects 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 15
- 229940126534 drug product Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 37
- -1 alkoxy radical Chemical class 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 20
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 20
- 229960003987 melatonin Drugs 0.000 claims description 19
- ZUVKZCTUVRLOAQ-UHFFFAOYSA-N quinolizin-4-one Chemical compound C1=CC=CN2C(=O)C=CC=C21 ZUVKZCTUVRLOAQ-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 17
- 238000006407 Bischler-Napieralski reaction Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 12
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 150000003254 radicals Chemical class 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- ZIXWTPREILQLAC-UHFFFAOYSA-N isoquinolin-8-ol Chemical compound C1=NC=C2C(O)=CC=CC2=C1 ZIXWTPREILQLAC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001624 sedative effect Effects 0.000 claims description 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- MVKKPOCFDDPESW-UHFFFAOYSA-N 1-ethyl-9-methoxy-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound N1C2=CC=C(OC)C=C2C2=C1C1=C(CC)CCC(=O)N1CC2 MVKKPOCFDDPESW-UHFFFAOYSA-N 0.000 claims description 3
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims description 3
- SODDJRYBVPSGJR-UHFFFAOYSA-N 9-methoxy-1-(4-methylphenyl)-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizin-4-one Chemical compound C1CC(=O)N2CCC=3C4=CC(OC)=CC=C4NC=3C2C1C1=CC=C(C)C=C1 SODDJRYBVPSGJR-UHFFFAOYSA-N 0.000 claims description 3
- FONURDNZCZFYTM-UHFFFAOYSA-N 9-methoxy-1-[(4-methoxyphenyl)methyl]-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizin-4-one Chemical compound C1=CC(OC)=CC=C1CC1C2C(NC=3C4=CC(OC)=CC=3)=C4CCN2C(=O)CC1 FONURDNZCZFYTM-UHFFFAOYSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- 229940127554 medical product Drugs 0.000 claims description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims description 2
- IDLUSBACXZYFJG-UHFFFAOYSA-N 1,1-diethyl-9-methoxy-2,3,6,7,12,12b-hexahydroindolo[2,3-a]quinolizin-4-one Chemical compound C1=C(OC)C=C2C(CCN3C(=O)CCC(C43)(CC)CC)=C4NC2=C1 IDLUSBACXZYFJG-UHFFFAOYSA-N 0.000 claims description 2
- DGYQKSNSNWMJGZ-UHFFFAOYSA-N 1-ethyl-9-methoxy-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizine-4-thione Chemical compound C1=C(OC)C=C2C(CCN3C(=S)CCC(C43)CC)=C4NC2=C1 DGYQKSNSNWMJGZ-UHFFFAOYSA-N 0.000 claims description 2
- PCZGIXOHRSYTLO-UHFFFAOYSA-N 1-ethyl-9-methoxy-3,12-dihydro-2h-indolo[2,3-a]quinolizine-4-thione Chemical compound N1C2=CC=C(OC)C=C2C2=C1C1=C(CC)CCC(=S)N1C=C2 PCZGIXOHRSYTLO-UHFFFAOYSA-N 0.000 claims description 2
- ZAJMLLXFZMEWMI-UHFFFAOYSA-N 1-ethyl-9-methoxy-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizine-4-thione Chemical compound N1C2=CC=C(OC)C=C2C2=C1C1=C(CC)CCC(=S)N1CC2 ZAJMLLXFZMEWMI-UHFFFAOYSA-N 0.000 claims description 2
- OTILMDASSITMIX-UHFFFAOYSA-N 9-methoxy-1-phenyl-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizine-4-thione Chemical compound C1CC(=S)N2CCC=3C4=CC(OC)=CC=C4NC=3C2C1C1=CC=CC=C1 OTILMDASSITMIX-UHFFFAOYSA-N 0.000 claims description 2
- BYKMMGKCDGIDKL-UHFFFAOYSA-N 9-methoxy-1-phenyl-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound C12=CC(OC)=CC=C2NC(C=23)=C1CCN3C(=O)CCC=2C1=CC=CC=C1 BYKMMGKCDGIDKL-UHFFFAOYSA-N 0.000 claims description 2
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- ZMZTUEGBIFSFIF-KRWDZBQOSA-N ethyl (6s)-1-ethyl-9-methoxy-4-oxo-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizine-6-carboxylate Chemical compound C12=C(CC)CCC(=O)N2[C@H](C(=O)OCC)CC2=C1NC1=CC=C(OC)C=C21 ZMZTUEGBIFSFIF-KRWDZBQOSA-N 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- OKTLTGDCVVQURW-UHFFFAOYSA-N 1-(4-aminophenyl)-9-methoxy-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizin-4-one Chemical compound C1CC(=O)N2CCC=3C4=CC(OC)=CC=C4NC=3C2C1C1=CC=C(N)C=C1 OKTLTGDCVVQURW-UHFFFAOYSA-N 0.000 claims 1
- DDANNPKRFBIOTL-UHFFFAOYSA-N 1-(4-fluorophenyl)-9-methoxy-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound C12=CC(OC)=CC=C2NC(C=23)=C1CCN3C(=O)CCC=2C1=CC=C(F)C=C1 DDANNPKRFBIOTL-UHFFFAOYSA-N 0.000 claims 1
- FONZCNXTIITBKG-UHFFFAOYSA-N 1-ethyl-9-methoxy-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizin-4-one Chemical compound C1=C(OC)C=C2C(CCN3C(=O)CCC(C43)CC)=C4NC2=C1 FONZCNXTIITBKG-UHFFFAOYSA-N 0.000 claims 1
- VEMCQTONMXMDHM-UHFFFAOYSA-N 1-hexyl-9-methoxy-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound N1C2=CC=C(OC)C=C2C2=C1C1=C(CCCCCC)CCC(=O)N1CC2 VEMCQTONMXMDHM-UHFFFAOYSA-N 0.000 claims 1
- GSLSBSNAZBFEHN-UHFFFAOYSA-N 9-methoxy-1-(4-methoxyphenyl)-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound C1=CC(OC)=CC=C1C1=C2C(NC=3C4=CC(OC)=CC=3)=C4CCN2C(=O)CC1 GSLSBSNAZBFEHN-UHFFFAOYSA-N 0.000 claims 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims 1
- HNUALPPJLMYHDK-UHFFFAOYSA-N C[CH]C Chemical compound C[CH]C HNUALPPJLMYHDK-UHFFFAOYSA-N 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 230000003509 anti-fertility effect Effects 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000000978 myorelaxation Effects 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 76
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 69
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 238000002844 melting Methods 0.000 description 29
- 230000008018 melting Effects 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000001819 mass spectrum Methods 0.000 description 18
- 230000007958 sleep Effects 0.000 description 18
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 17
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 15
- 238000001704 evaporation Methods 0.000 description 15
- 230000008020 evaporation Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 235000013330 chicken meat Nutrition 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 239000008096 xylene Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 125000003710 aryl alkyl group Chemical group 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 125000003282 alkyl amino group Chemical group 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 7
- 125000005110 aryl thio group Chemical group 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 7
- 125000005366 cycloalkylthio group Chemical group 0.000 description 7
- 125000004663 dialkyl amino group Chemical group 0.000 description 7
- 125000004986 diarylamino group Chemical group 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- 206010062519 Poor quality sleep Diseases 0.000 description 6
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 6
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 6
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 6
- 125000001769 aryl amino group Chemical group 0.000 description 6
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 6
- 125000005129 aryl carbonyl group Chemical group 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 150000003857 carboxamides Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 101710202061 N-acetyltransferase Proteins 0.000 description 5
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 5
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 5
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 5
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000037322 slow-wave sleep Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 4
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 4
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 4
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- UZUODNWWWUQRIR-UHFFFAOYSA-L disodium;3-aminonaphthalene-1,5-disulfonate Chemical compound [Na+].[Na+].C1=CC=C(S([O-])(=O)=O)C2=CC(N)=CC(S([O-])(=O)=O)=C21 UZUODNWWWUQRIR-UHFFFAOYSA-L 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000037321 sleepiness Effects 0.000 description 3
- JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 description 2
- AHKNGDBVCRMQHC-UHFFFAOYSA-N 9-methoxy-1-(4-nitrophenyl)-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound C12=CC(OC)=CC=C2NC(C=23)=C1CCN3C(=O)CCC=2C1=CC=C([N+]([O-])=O)C=C1 AHKNGDBVCRMQHC-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- HJZVHUQSQGITAM-UHFFFAOYSA-N butanamide Chemical compound CC[CH]C(N)=O HJZVHUQSQGITAM-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- BLNWTAHYTCHDJH-UHFFFAOYSA-O hydroxy(oxo)azanium Chemical group O[NH+]=O BLNWTAHYTCHDJH-UHFFFAOYSA-O 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- KIHVPIRTWGPOKL-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]butanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCC)=CNC2=C1 KIHVPIRTWGPOKL-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- PVRSIFAEUCUJPK-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine Chemical compound COC1=CC=C(NN)C=C1 PVRSIFAEUCUJPK-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- RGJKJXYTDNJQKT-UHFFFAOYSA-N 1,10-diethyl-9-methoxy-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound N1C2=CC(CC)=C(OC)C=C2C2=C1C1=C(CC)CCC(=O)N1CC2 RGJKJXYTDNJQKT-UHFFFAOYSA-N 0.000 description 1
- OSIQNHXQSRQESI-UHFFFAOYSA-N 11-ethyl-3-methoxy-5,6,9,10-tetrahydronaphtho[2,1-a]quinolizin-8-one Chemical compound C1=CC2=CC=C(OC)C=C2C2=C1C1=C(CC)CCC(=O)N1CC2 OSIQNHXQSRQESI-UHFFFAOYSA-N 0.000 description 1
- QHLPHUHZBFAHCR-UHFFFAOYSA-N 11-ethyl-3-methoxy-5,6,9,10-tetrahydronaphtho[2,1-a]quinolizine-8-thione Chemical compound C1=CC2=CC=C(OC)C=C2C2=C1C1=C(CC)CCC(=S)N1CC2 QHLPHUHZBFAHCR-UHFFFAOYSA-N 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- GVTQSQDRIMZRMF-UHFFFAOYSA-N 3-methoxy-11-phenyl-5,6,9,10-tetrahydronaphtho[2,1-a]quinolizin-8-one Chemical compound C1CC(=O)N2CCC=3C4=CC(OC)=CC=C4C=CC=3C2=C1C1=CC=CC=C1 GVTQSQDRIMZRMF-UHFFFAOYSA-N 0.000 description 1
- NKNLETXQNBOAOZ-UHFFFAOYSA-N 3-methoxy-11-phenyl-5,6,9,10-tetrahydronaphtho[2,1-a]quinolizine-8-thione Chemical compound C1CC(=S)N2CCC=3C4=CC(OC)=CC=C4C=CC=3C2=C1C1=CC=CC=C1 NKNLETXQNBOAOZ-UHFFFAOYSA-N 0.000 description 1
- SNXSQWNZYLLXDA-UHFFFAOYSA-N 3-methylbutanamide Chemical compound [CH2]C(C)CC(N)=O SNXSQWNZYLLXDA-UHFFFAOYSA-N 0.000 description 1
- NTYXKFHKVREUMR-UHFFFAOYSA-N 4,9-dihydro-3h-pyrido[3,4-b]indole Chemical class N1C2=CC=CC=C2C2=C1C=NCC2 NTYXKFHKVREUMR-UHFFFAOYSA-N 0.000 description 1
- VNAGWSKMCITODC-UHFFFAOYSA-N 4-[4-(7-hydroxyheptoxy)phenyl]benzonitrile Chemical compound C1=CC(OCCCCCCCO)=CC=C1C1=CC=C(C#N)C=C1 VNAGWSKMCITODC-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical class C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 229940097276 5-methoxytryptamine Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- XAYFZNLBFRGQJN-UHFFFAOYSA-N 9-methoxy-1-(4-methylphenyl)-3,6,7,12-tetrahydro-2h-indolo[2,3-a]quinolizin-4-one Chemical compound C12=CC(OC)=CC=C2NC(C=23)=C1CCN3C(=O)CCC=2C1=CC=C(C)C=C1 XAYFZNLBFRGQJN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000001573 Cataplexy Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000006641 Fischer synthesis reaction Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005001 aminoaryl group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- HMBHRMFLDKKSCT-UHFFFAOYSA-N chembl338115 Chemical compound C12=CC(OC)=CC=C2NC2=C1CCN=C2C HMBHRMFLDKKSCT-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- UEWPOAUUMRKKAH-HNNXBMFYSA-N ethyl (2s)-2-amino-3-(1-butanoyl-5-methoxyindol-3-yl)propanoate Chemical compound COC1=CC=C2N(C(=O)CCC)C=C(C[C@H](N)C(=O)OCC)C2=C1 UEWPOAUUMRKKAH-HNNXBMFYSA-N 0.000 description 1
- HPNXVRSHSPWXKO-UHFFFAOYSA-N ethyl 3-[2-(5-methoxy-1h-indol-3-yl)ethylamino]-3-oxopropanoate Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC(=O)OCC)=CNC2=C1 HPNXVRSHSPWXKO-UHFFFAOYSA-N 0.000 description 1
- HASJWDPFBRPJNC-UHFFFAOYSA-N ethyl 4-[(4-ethoxycarbonylanilino)methylamino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NCNC1=CC=C(C(=O)OCC)C=C1 HASJWDPFBRPJNC-UHFFFAOYSA-N 0.000 description 1
- YOOOYFXZRURNQR-UHFFFAOYSA-N ethyl 9-methoxy-4-oxo-2,3,6,7,12,12b-hexahydro-1h-indolo[2,3-a]quinolizine-1-carboxylate Chemical compound C1=C(OC)C=C2C(CCN3C(=O)CCC(C43)C(=O)OCC)=C4NC2=C1 YOOOYFXZRURNQR-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SUDWKCFOUYLIBM-UHFFFAOYSA-N n-(4,4-diethoxybutyl)butanamide Chemical compound CCCC(=O)NCCCC(OCC)OCC SUDWKCFOUYLIBM-UHFFFAOYSA-N 0.000 description 1
- LKEASSBALFKZEU-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NCCC1=CNC2=CC=C(OC)C=C12 LKEASSBALFKZEU-UHFFFAOYSA-N 0.000 description 1
- VUSLQYSJAVHCLS-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-2-(4-methylphenyl)acetamide Chemical compound C12=CC(OC)=CC=C2NC=C1CCNC(=O)CC1=CC=C(C)C=C1 VUSLQYSJAVHCLS-UHFFFAOYSA-N 0.000 description 1
- MMDQDKPDWJZCKM-UHFFFAOYSA-N n-[2-(7-methoxynaphthalen-1-yl)ethyl]-2-phenylacetamide Chemical compound C12=CC(OC)=CC=C2C=CC=C1CCNC(=O)CC1=CC=CC=C1 MMDQDKPDWJZCKM-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004999 nitroaryl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- UBAOFCNBCAZEBL-UHFFFAOYSA-N octanamide Chemical compound CCCCCCCC(N)=O.CCCCCCCC(N)=O UBAOFCNBCAZEBL-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- GFVCKPOKLSSKMM-UHFFFAOYSA-N quinolizine-4-thione Chemical compound C1=CC=CN2C(=S)C=CC=C21 GFVCKPOKLSSKMM-UHFFFAOYSA-N 0.000 description 1
- 230000004461 rapid eye movement Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000004599 slow eye movement Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/042,990 US6048868A (en) | 1994-09-14 | 1998-03-17 | Melatonin-antagonist β-carboline derivatives and analogues thereof containing naphthalenic structure, process for their preparation and their use as medicinal products |
| PCT/IB1999/000494 WO1999047521A1 (en) | 1998-03-17 | 1999-03-17 | HYPNOTIC β-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20004638D0 NO20004638D0 (no) | 2000-09-15 |
| NO20004638L NO20004638L (no) | 2000-11-16 |
| NO317296B1 true NO317296B1 (no) | 2004-10-04 |
Family
ID=21924862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004638A NO317296B1 (no) | 1998-03-17 | 2000-09-15 | Hypnotisk <beta>- karbolinderivater, fremgangsmater til deres fremstilling og deres anvendelse som legemiddelprodukt |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1064284B1 (ja) |
| JP (1) | JP4333036B2 (ja) |
| CN (1) | CN1115342C (ja) |
| AR (1) | AR018767A1 (ja) |
| AT (1) | ATE215087T1 (ja) |
| AU (1) | AU752364B2 (ja) |
| BG (1) | BG63973B1 (ja) |
| BR (1) | BR9908833A (ja) |
| CA (1) | CA2324270A1 (ja) |
| DE (1) | DE69901098T2 (ja) |
| DK (1) | DK1064284T3 (ja) |
| ES (1) | ES2174632T3 (ja) |
| HU (1) | HUP0101234A3 (ja) |
| IL (1) | IL138442A (ja) |
| IS (1) | IS2199B (ja) |
| NO (1) | NO317296B1 (ja) |
| NZ (1) | NZ506913A (ja) |
| PL (1) | PL193450B1 (ja) |
| PT (1) | PT1064284E (ja) |
| RU (1) | RU2210571C2 (ja) |
| SK (1) | SK284387B6 (ja) |
| TR (1) | TR200003596T2 (ja) |
| UA (1) | UA71911C2 (ja) |
| WO (1) | WO1999047521A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2824829B1 (fr) * | 2001-05-16 | 2005-06-03 | Macef | Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament |
| FR2904973A1 (fr) * | 2006-08-18 | 2008-02-22 | Fourtillan Snc | Derives de 1-methylidene-pyrido[3,4-b]indole et leur utilisation en therapeutique. |
| FR2916200A1 (fr) * | 2007-05-18 | 2008-11-21 | Fourtillan Snc | Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique |
| EP2240481A1 (en) | 2008-01-11 | 2010-10-20 | Albany Molecular Research, Inc. | (1-azinone) -substituted pyridoindoles as mch antagonists |
| US8629158B2 (en) | 2009-07-01 | 2014-01-14 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| WO2011003005A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
| WO2011003021A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| WO2011003012A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| WO2012088038A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof |
| WO2012088124A2 (en) | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
| FI130627B (en) * | 2021-03-31 | 2023-12-18 | Equinorm Ltd | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283343A (en) * | 1987-08-17 | 1994-02-01 | Whitby Research, Inc. | 2-aryl substituted N-acetyltryptamines and process of preparing such |
| FR2724384B1 (fr) * | 1994-09-14 | 1999-04-16 | Cemaf | Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament |
-
1999
- 1999-03-17 AT AT99939844T patent/ATE215087T1/de not_active IP Right Cessation
- 1999-03-17 PL PL99342929A patent/PL193450B1/pl not_active IP Right Cessation
- 1999-03-17 DK DK99939844T patent/DK1064284T3/da active
- 1999-03-17 CA CA002324270A patent/CA2324270A1/en not_active Abandoned
- 1999-03-17 JP JP2000536716A patent/JP4333036B2/ja not_active Expired - Fee Related
- 1999-03-17 CN CN99805687A patent/CN1115342C/zh not_active Expired - Fee Related
- 1999-03-17 TR TR2000/03596T patent/TR200003596T2/xx unknown
- 1999-03-17 HU HU0101234A patent/HUP0101234A3/hu unknown
- 1999-03-17 ES ES99939844T patent/ES2174632T3/es not_active Expired - Lifetime
- 1999-03-17 IL IL138442A patent/IL138442A/en not_active IP Right Cessation
- 1999-03-17 RU RU2000126288/04A patent/RU2210571C2/ru not_active IP Right Cessation
- 1999-03-17 AR ARP990101166A patent/AR018767A1/es active IP Right Grant
- 1999-03-17 DE DE69901098T patent/DE69901098T2/de not_active Expired - Lifetime
- 1999-03-17 EP EP99939844A patent/EP1064284B1/en not_active Expired - Lifetime
- 1999-03-17 NZ NZ506913A patent/NZ506913A/en unknown
- 1999-03-17 UA UA2000105839A patent/UA71911C2/uk unknown
- 1999-03-17 AU AU32707/99A patent/AU752364B2/en not_active Ceased
- 1999-03-17 PT PT99939844T patent/PT1064284E/pt unknown
- 1999-03-17 WO PCT/IB1999/000494 patent/WO1999047521A1/en active IP Right Grant
- 1999-03-17 SK SK1385-2000A patent/SK284387B6/sk not_active IP Right Cessation
- 1999-03-17 BR BR9908833-9A patent/BR9908833A/pt not_active Application Discontinuation
-
2000
- 2000-09-12 IS IS5627A patent/IS2199B/is unknown
- 2000-09-14 BG BG104768A patent/BG63973B1/bg unknown
- 2000-09-15 NO NO20004638A patent/NO317296B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4051712B2 (ja) | 新規メラトニン作用性のβ−カルボリン誘導体とナフタレン構造を含むその類似物、それらの製造方法および医薬品としての用途 | |
| JPWO2006051704A1 (ja) | イミン化合物 | |
| JP4691506B2 (ja) | カゼインキナーゼＩεの阻害剤としての置換１Ｈ−ピロロ［３，２−ｂ，３，２−ｃ，及び２，３−ｃ］ピリジン−２−カルボキシアミド及び関連類似物 | |
| HRP20020910A2 (en) | -carboline derivatives useful as inhibitors of phosphodiesterase | |
| JP2005514366A (ja) | ３−置換オキシインドールβ３アゴニスト | |
| JP2010518026A (ja) | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 | |
| JPH09291034A (ja) | 縮合ピリジン化合物およびその医薬としての用途 | |
| JP2009509928A (ja) | カリウムチャンネル開口剤としての新規ベンゾピラン誘導体 | |
| NO317296B1 (no) | Hypnotisk <beta>- karbolinderivater, fremgangsmater til deres fremstilling og deres anvendelse som legemiddelprodukt | |
| CA2917602A1 (en) | 1,7-naphthyridine derivatives | |
| CN101481323B (zh) | 苯并环庚烯类衍生物、其制备方法及医药用途 | |
| JP7041141B2 (ja) | 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
| KR20100036306A (ko) | 치료용 피라졸로나프티리딘 유도체 | |
| CA2437215A1 (en) | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | |
| JP2009509927A (ja) | カリウムチャンネル開口剤としての新規ベンゾピラン誘導体 | |
| JP6033788B2 (ja) | 置換されたメチルアミン、セロトニン５−ｈｔ６受容体アンタゴニスト、製造のための方法及びその使用 | |
| KR880000045B1 (ko) | 벤조디아제핀 화합물의 제조 방법 | |
| EP2935254A1 (en) | Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them | |
| NO162188B (no) | Analogifremgangsm te for fremstilling av terapeutisk aktive imidazokinoliner. | |
| TWI564300B (zh) | 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑 | |
| JP4008059B2 (ja) | 松果体ホルモン作用薬 | |
| CZ20003279A3 (cs) | Uspávači beta karbolinové deriváty, způsob jejich přípravy a použití v lékařství | |
| GB2448808A (en) | Substituted imidazo[1,2-a]pyridines and their use as agonists at GABA-A receptors for treating or preventing neurological or psychiatric disorders | |
| MXPA00009139A (en) | HYPNOTIC&bgr;-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS | |
| WO2010066253A1 (en) | Selective inhibitors of excitatory amino acid transporter subtype 1 (eaat1 /glast) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |